Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NanoPac in Mucinous Cystic Pancreatic Neoplasms
NCT03188991Phase 2Completed
- Sponsor
- NanOlogy
- Start
- Sep 2017
- Primary completion
- Jun 2020
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of NanoPac in mucinous cystic pancreatic neoplasm (MCPN) (4 arms), sponsored by NanOlogy. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events at 6 months. Started Sep 2017; status: completed.
02
Drugs
NanoPac
03
Conditions
mucinous cystic pancreatic neoplasm (MCPN)
Beyond the preview
Go deeper on NCT03188991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03188991.